Sperling Prostate Center

Category: Prostate Cancer

A First-of-its-Kind Vaccine to Prevent Prostate Cancer Recurrence

Prostate Cancer Vaccine | Sperling Prostate Center
Here is fantastic news for men who undergo an initial treatment for localized prostate cancer! In November, 2020 the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to RV001, an investigational vaccine against prostate cancer recurrence after primary treatment. RV001 is manufactured by a Swedish pharmaceutical company called RhoVac. Let’s look at the keep reading

This content is solely for informational purposes and does not substitute for diagnostic or medical advice. Talk to your doctor or contact us if you have questions or concerns of a personal, medical nature. This site uses cookies to analyze traffic and user behavior, protect your privacy, and provide you with the best user experience. Learn more. 
close-image
An update on COVID-19: Your health and safety are our top priority.
Learn More
close-image
WordPress Image Lightbox